Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6556 to 6570 of 8314 results

  1. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Technology appraisal guidance
    Published
    22 January 2020

  2. Newer drugs for epilepsy in children (TA79)

    This guideline has been updated and replaced by NICE guideline CG137.

    Technology appraisal guidance
    Published
    28 April 2004

  3. Implantable cardioverter defibrillators for arrhythmias (TA95)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Technology appraisal guidance
    Published
    25 January 2006

  4. Computerised cognitive behaviour therapy for depression and anxiety (TA97)

    The guidance was withdrawn in July 2018 to allow OCFighter to be considered for an improving access to psychological therapies assessment briefing. If OCFighter is not selected, it may be considered for a medtech innovation briefing.

    Technology appraisal guidance
    Published
    22 February 2006

  5. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

    This guidance has been updated and replaced by NICE guideline NG87.

    Technology appraisal guidance
    Published
    22 March 2006

  6. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Technology appraisal guidance
    Published
    27 January 2016

  7. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)

    This guidance has been updated and replaced by NICE technology appraisal guidance 412.

    Technology appraisal guidance
    Published
    27 January 2016

  8. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10. 

    Technology appraisal guidance
    Published
    27 March 2002

  9. Apremilast for treating moderate to severe plaque psoriasis (TA368)

    Technology appraisal guidance
    Published
    25 November 2015

  10. The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma (TA37)

    This guidance has been updated and replaced by NICE technology appraisal guidance 137.

    Technology appraisal guidance
    Published
    27 March 2002

  11. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Technology appraisal guidance
    Published
    27 March 2002

  12. Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)

    This guidance has been updated and replaced by NICE technology appraisal guidance 476.

    Technology appraisal guidance
    Published
    28 October 2015

  13. Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)

    The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

    Technology appraisal guidance
    Published
    28 October 2015

  14. Daclatasvir for treating chronic hepatitis C (TA364)

    This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).

    Technology appraisal guidance
    Published
    25 November 2015

  15. Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371)

    This guidance has been updated and replaced by NICE technology appraisal guidance 458.

    Technology appraisal guidance
    Published
    16 December 2015